7Baggers
 Published on: 2025-11-16 01:00:56  newser.com Sun, 16 Nov 2025 07:00:56 GMT
 Oppenheimer Maintains Cellectar BioSciences(CLRB.US) With Hold Rating  富途牛牛 Sat, 15 Nov 2025 04:48:46 GMT
 Cellectar Biosciences Reports Q3 2025 Financial Progress  TipRanks Fri, 14 Nov 2025 04:34:26 GMT
 cellectar biosciences q3 2025 earnings call transcript  MarketBeat Fri, 14 Nov 2025 02:12:21 GMT
 Cellectar Biosciences: Positive Outlook Amidst Challenges  TipRanks Fri, 14 Nov 2025 00:42:53 GMT
 Cellectar Biosciences (CLRB) Highlights Q3 2025 Progress and Fut  GuruFocus Thu, 13 Nov 2025 21:06:57 GMT
 Cellectar Biosciences reports Q3 EPS ($1.41), consensus ($2.53)  TipRanks Thu, 13 Nov 2025 17:02:42 GMT
 Cellectar Biosciences Q3 2025 Earnings Call Transcript  MarketBeat Thu, 13 Nov 2025 15:45:00 GMT
 Cellectar (CLRB) Advances Regulatory Strategy for Iopofosine I-1  GuruFocus Thu, 13 Nov 2025 13:16:17 GMT
 Cellectar Biosciences Q3 net loss narrows to $4.4 mln  MarketScreener Thu, 13 Nov 2025 12:32:00 GMT
 Earnings Outlook For Cellectar Biosciences  Benzinga Wed, 12 Nov 2025 17:03:34 GMT
 Cellectar Biosciences to Report Third Quarter Financial  GlobeNewswire Thu, 06 Nov 2025 13:05:00 GMT
 published on: 2025-11-06 05:20:07  newser.com Thu, 06 Nov 2025 11:20:07 GMT
 published on: 2025-11-05 00:24:30  newser.com Wed, 05 Nov 2025 06:24:30 GMT

Cellectar Biosciences, Inc
(NASDAQ:CLRB) 

CLRB stock logo

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refr...

Founded: 1996
Full Time Employees: 8
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends